Patents by Inventor Steven Paul Hanlon

Steven Paul Hanlon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUNDS
    Publication number: 20220267349
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, Q, U, V, W, X, Z, m, n, and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: January 31, 2022
    Publication date: August 25, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Steven Paul HANLON, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Martin KURATLI, Guofu LIU, Fionn O`HARA, Hans RICHTER, Martin RITTER
  • HETEROCYCLIC COMPOUNDS
    Publication number: 20210107921
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, Q, U, V, W, X, Z, m, n, and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 21, 2020
    Publication date: April 15, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Steven Paul HANLON, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Martin KURATLI, Guofu LIU, Fionn O`HARA, Hans RICHTER, Martin RITTER
  • Mutant transaminases as well as methods and uses relating thereto
    Patent number: 10017749
    Abstract: The present invention relates to a mutant transaminase with increased transaminase activity relative to the wild-type transaminase, a fusion protein comprising the transaminase, a polynucleotide coding for the transaminase, a host cell comprising the polynucleotide, mutant transaminase and/or fusion protein, a method of producing an amine with the mutant transaminase or fusion protein and the use of the mutant transaminase or fusion protein for the production of an amine.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: July 10, 2018
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Steven Paul Hanlon, Hans Iding, Paul Spurr, Beat Wirz, Uwe Bornscheuer, Ioannis Pavlidis, Martin Steffen Weiss
  • MUTANT TRANSAMINASES AS WELL AS METHODS AND USES RELATING THERETO
    Publication number: 20160304843
    Abstract: The present invention relates to a mutant transaminase with increased transaminase activity relative to the wild-type transaminase, a fusion protein comprising the transaminase, a polynucleotide coding for the transaminase, a host cell comprising the polynucleotide, mutant transaminase and/or fusion protein, a method of producing an amine with the mutant transaminase or fusion protein and the use of the mutant transaminase or fusion protein for the production of an amine.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Steven Paul HANLON, Hans IDING, Paul SPURR, Beat WIRZ, Uwe BORNSCHEUER, Ioannis PAVLIDIS, Martin Steffen WEISS
  • Process for the preparation of isoxazolyl-methoxy nicotinic acids
    Patent number: 8604062
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I) wherein R1 and R2 are as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: December 10, 2013
    Assignee: Hoffman-La Roche Inc.
    Inventors: Pascal Dott, Steven Paul Hanlon, Stefan Hildbrand, Hans Iding, Andrew Thomas, Pius Waldmeier
  • Substituted isoxazoles
    Patent number: 8222246
    Abstract: The present invention is concerned with novel hydroxy-methyl isoxazole derivatives of formula I wherein R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A ?5 receptor. Further the present invention is concerned with the manufacture of the active compounds of formula I, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: July 17, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Stephen Deems Gabriel, Steven Paul Hanlon, Roland Jakob-Roetne, Matthew C. Lucas, Paul Spurr, Andrew Thomas, Pius Waldmeier
  • SUBSTITUTED ISOXAZOLES
    Publication number: 20100256127
    Abstract: The present invention is concerned with novel hydroxy-methyl isoxazole derivatives of formula I wherein R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A ?5 receptor. Further the present invention is concerned with the manufacture of the active compounds of formula I, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Application
    Filed: March 29, 2010
    Publication date: October 7, 2010
    Inventors: Bernd Buettelmann, Stephen Deems Gabriel, Steven Paul Hanlon, Roland Jakob-Roetne, Matthew C. Lucas, Paul Spurr, Andrew Thomas, Pius Waldmeier
  • Biocatalytic asymmetric reduction in preparation of (S)-N-[5-(1,2-dihydroxy-ethyl)-pyrazinyl]-2,2-dimethyl-propionamide
    Patent number: 7727750
    Abstract: The present invention relates to biocatalytic asymmetric reduction for the preparation of 2-amino-[5-(1-hydroxy-2-hydroxy or halogen-ethyl)]-pyrazine derivatives of the formula wherein R is lower alkylcarbonyl or an amino protecting group and R1 is hydroxy or halogen. The compounds are key intermediates in the manufacture of a glucokinase activator.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: June 1, 2010
    Assignee: Hoffman-La Roche Inc.
    Inventors: Steven Paul Hanlon, Hans Iding, Ernst Kupfer, Roumen Nikolaev Radinov, Lianhe Shu, Ping Wang
  • BIOCATALYTIC ASYMMETRIC REDUCTION IN PREPARATION OF (S)-N-[5-(1,2-DIHYDROXY-ETHYL)-PYRAZINYL]-2,2-DIMETHYL-PROPIONAMIDE
    Publication number: 20080248537
    Abstract: The present invention relates to biocatalytic asymmetric reduction for the preparation of 2-amino-[5-(1-hydroxy-2-hydroxy or halogen-ethyl)]-pyrazine derivatives of the formula wherein R is lower alkylcarbonyl or an amino protecting group and R1 is hydroxy or halogen. The compounds are key intermediates in the manufacture of a glucokinase activator.
    Type: Application
    Filed: April 3, 2008
    Publication date: October 9, 2008
    Inventors: Steven Paul Hanlon, Hans Iding, Ernst Kupfer, Roumen Nikolaev Radinov, Lianhe Shu, Ping Wang
  • Asymmetric reduction of 1,1,1-trifluoroacetone
    Patent number: 7196234
    Abstract: The invention relates to a scalable biocatalytic process for the preparation of S-1,1,1-trifluoro-2-propanol with a enantiomeric excess of >99% by asymmetric microbial reduction of 1,1,1-trifluoroacetone with Baker's yeast.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: March 27, 2007
    Assignee: Hoffman-La Roche Inc.
    Inventors: Stephan Doswald, Steven Paul Hanlon, Ernst Kupfer